Table 1. Characteristics of the patients.

Characteristics	No. of patients	Expression of FBP1		P-value	Expression of c-Myc		P-value
		Low	High		Low	High
Patients	83	41	42		41	42
Age
Median	46
Range	24~77
≤46	43	24	19	0.225	9	34	0.305
>46	40	17	23		5	35
Gender
Female	19	2	17	0.506	2	17	0.506
Male	64	12	52		12	52
T classification
T1–T2	21	11	10	0.752	3	18	1.000
T3–T4	62	30	32		11	51
N classification
N0–N1	33	19	14	0.226	9	24	0.040
N2–N3	50	22	28		5	45
Clinical stage
I–II	8	4	4	<0.001	2	6	0.022
III–IV	75	37	38		12	63
EBV-DNA
<3200	44	18	44	0.931	7	37	0.804
≥3200	39	15	24		7	32
EBV-VCA-IgA
<1:160	19	7	12	0.440	4	15	0.439
≥1:160	64	30	64		19	54
EBV-EAIA2-IgA
<1 : 20	33	15	18	0.559	6	27	0.795
≥1 : 20	50	26	24		8	42
Locoregional failure
Yes	2	0	2	0.049	0	2	1.000
No	81	41	40		14	67
Distant metastasis
Yes	18	5	13	0.038	1	17	0.284
No	65	36	29		13	52
Tumor progression
Yes	19	1	18	0.172	13	51	0.172
No	64	13	51		1	18
Death
Yes	12	3	9	0.068	1	11	0.681
No	71	38	33		13	58

Abbreviations: EBV, Epstein–Barr virus; FBP1, far upstream element-binding protein 1